{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179837","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.604722+00:00","generated_at":"2026-05-17T13:57:07.563797+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate","bullets":["Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.","Cash, cash equivalents and marketable securities $490.5M as of June 30, 2025; cash runway into first half of 2029.","Net loss of $25.3M for Q2 2025 vs $20.0M in Q2 2024; R&D expenses $21.5M, G&A $7.1M.","Company plans to initiate Phase 3 pivotal trial of ELVN-001 in 2026.","Recent public offering generated $230M gross proceeds, strengthening balance sheet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179837","json":"https://secwatch.observer/filing/0001193125-25-179837.json","markdown":"https://secwatch.observer/filing/0001193125-25-179837.md","text":"https://secwatch.observer/filing/0001193125-25-179837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/0001193125-25-179837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/elvn-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:07.563797+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}